解放军医学院学报Issue(7)：751-754,4.DOI:10.3969/j.issn.2095-5227.2015.07.029
非小细胞肺癌术后表皮生长因子受体-酪氨酸激酶抑制剂辅助治疗研究进展
Advances in EGFR-TKIs as adjuvant therapy in post-surgery of non-small cell lung cancer
摘要
Abstract
Lung cancer is the most common malignant disease with the highest mortality, among which non-small cell lung cancer (NSCLC) accounts for nearly 85%of all cases. The first-line treatment for NSCLC is surgery, followed by chemotherapy in order to improve overall survival. However, only 4%-15%patients demonstrate improved treatment benefit, while chemotherapy-related side effects greatly worsen the quality of life and increase non-tumor-related mortality. EGFR-TKIs are important treatment options for late stage NSCLC with EGFR mutations. Whether or not EGFR-TKIs can be used in intermediate stage NSCLC needs further validation. In this article, we review and discuss the topics on EGFR-TKIs as adjuvant therapy in post-surgery of NSCLC.关键词
非小细胞肺癌/表皮生长因子受体-酪氨酸激酶抑制剂/肿瘤治疗Key words
non-small cell lung cancer/epidermal growth factor receptor-tyrosine kinase inhibitors/tumor therapy分类
医药卫生引用本文复制引用
刘哲峰,焦顺昌..非小细胞肺癌术后表皮生长因子受体-酪氨酸激酶抑制剂辅助治疗研究进展[J].解放军医学院学报,2015,(7):751-754,4.基金项目
国家自然科学基金项目(81173178) （81173178）
